"The US government has launched an investigation into whether Germany systematically underpays for innovative drugs. The dispute centers on the proposed 'GKV-Beitragsstabilisierungsgesetz' (GKV Contribution Stabilization Act). The US trade representative suggests this could lead to punitive tariffs on German goods."